ZA200403711B - Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same. - Google Patents

Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same. Download PDF

Info

Publication number
ZA200403711B
ZA200403711B ZA200403711A ZA200403711A ZA200403711B ZA 200403711 B ZA200403711 B ZA 200403711B ZA 200403711 A ZA200403711 A ZA 200403711A ZA 200403711 A ZA200403711 A ZA 200403711A ZA 200403711 B ZA200403711 B ZA 200403711B
Authority
ZA
South Africa
Prior art keywords
methyl
tetrahydro
dichloro
isoquinolin
phenyl
Prior art date
Application number
ZA200403711A
Other languages
English (en)
Inventor
Armin Hofmeister
Uwe Heinelt
Hans-Jochen Lang
Klaus Wirth
Michael Gekle
Markus Bleich
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ZA200403711B publication Critical patent/ZA200403711B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
ZA200403711A 2001-12-05 2004-05-14 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same. ZA200403711B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10159714 2001-12-05

Publications (1)

Publication Number Publication Date
ZA200403711B true ZA200403711B (en) 2005-06-09

Family

ID=7708117

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200403711A ZA200403711B (en) 2001-12-05 2004-05-14 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same.

Country Status (34)

Country Link
EP (1) EP1453810B1 (no)
JP (1) JP4510457B2 (no)
KR (1) KR20050044724A (no)
CN (1) CN100497314C (no)
AR (1) AR037620A1 (no)
AT (1) ATE425968T1 (no)
AU (1) AU2002356689B2 (no)
BR (1) BR0214753A (no)
CA (1) CA2469385A1 (no)
CO (1) CO5580748A2 (no)
DE (1) DE50213372D1 (no)
DK (1) DK1453810T3 (no)
EC (1) ECSP045138A (no)
ES (1) ES2324528T3 (no)
HK (1) HK1072597A1 (no)
HR (1) HRP20040507A2 (no)
HU (1) HUP0600854A2 (no)
IL (1) IL162316A0 (no)
MA (1) MA27147A1 (no)
MX (1) MXPA04005343A (no)
MY (1) MY157371A (no)
NO (1) NO326650B1 (no)
NZ (1) NZ533322A (no)
OA (1) OA12740A (no)
PE (1) PE20030726A1 (no)
PL (1) PL369313A1 (no)
PT (1) PT1453810E (no)
RS (1) RS48004A (no)
RU (1) RU2298003C2 (no)
TN (1) TNSN04100A1 (no)
TW (1) TWI281860B (no)
UA (1) UA77042C2 (no)
WO (1) WO2003048129A1 (no)
ZA (1) ZA200403711B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA94901C2 (ru) 2005-02-18 2011-06-25 Астразенека Аб Антибактериальные производные пиперидина
CN101171247A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 作为dna促旋酶和拓扑异构酶抑制剂的吡咯衍生物
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010078449A2 (en) * 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
RU2684097C2 (ru) * 2012-08-21 2019-04-04 Эрделикс, Инк. Соединения и способы для ингибирования NHE-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой, и заболеваний желудочно-кишечного тракта
BR112015025805A2 (pt) 2013-04-12 2017-07-25 Ardelyx Inc compostos de ligação de nh3 e métodos para inibir o transporte de fosfato
CN103788084A (zh) * 2014-03-02 2014-05-14 湖南华腾制药有限公司 四氢异喹啉衍生物及其合成方法
SI3173408T1 (sl) * 2014-07-25 2019-01-31 Taisho Pharmaceutical Co., Ltd., Spojina fenil tetrahidroizokinolin substituirana s heteroarilom
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN110267944B (zh) * 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
WO2022127917A1 (zh) * 2020-12-18 2022-06-23 上海济煜医药科技有限公司 苯并杂环取代四氢异喹啉类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
KR100885986B1 (ko) * 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
BR0015307A (pt) * 1999-11-03 2002-07-09 Albany Molecular Res Inc Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Also Published As

Publication number Publication date
RU2004120295A (ru) 2006-01-10
NO326650B1 (no) 2009-01-26
UA77042C2 (en) 2006-10-16
CN100497314C (zh) 2009-06-10
CO5580748A2 (es) 2005-11-30
WO2003048129A1 (de) 2003-06-12
HRP20040507A2 (en) 2005-08-31
MY157371A (en) 2016-06-15
DE50213372D1 (de) 2009-04-30
IL162316A0 (en) 2005-11-20
BR0214753A (pt) 2004-12-14
RU2298003C2 (ru) 2007-04-27
ES2324528T3 (es) 2009-08-10
AU2002356689A1 (en) 2003-06-17
AU2002356689B2 (en) 2008-05-15
RS48004A (en) 2006-10-27
JP2005515205A (ja) 2005-05-26
OA12740A (en) 2006-06-30
JP4510457B2 (ja) 2010-07-21
NZ533322A (en) 2006-02-24
CA2469385A1 (en) 2003-06-12
HUP0600854A2 (en) 2007-02-28
AR037620A1 (es) 2004-11-17
TWI281860B (en) 2007-06-01
MXPA04005343A (es) 2004-09-27
EP1453810A1 (de) 2004-09-08
PT1453810E (pt) 2009-05-27
PL369313A1 (en) 2005-04-18
EP1453810B1 (de) 2009-03-18
MA27147A1 (fr) 2005-01-03
ECSP045138A (es) 2004-08-27
ATE425968T1 (de) 2009-04-15
HK1072597A1 (en) 2005-09-02
TW200306190A (en) 2003-11-16
DK1453810T3 (da) 2009-07-20
TNSN04100A1 (en) 2006-06-01
CN1617856A (zh) 2005-05-18
NO20042158L (no) 2004-08-27
PE20030726A1 (es) 2003-09-30
KR20050044724A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
ZA200403711B (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same.
RU2201927C2 (ru) Амидиновые соединения и фармацевтическая композиция, обладающая фактор ха ингибирующим действием
EP0912512B1 (en) Sulphonamide derivatives and their use in the treatment of cns disorders
JP6538266B2 (ja) ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾールスルファミド誘導体化合物及びこれを含有する薬剤学的組成物(1,3,4−Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same)
RU2002125860A (ru) Новые производные циклического амида
RU2354653C2 (ru) Производные 1-(2-аминобензол)пиперазина, используемые в качестве ингибиторов поглощения глицина и предназначенные для лечения психоза
CA2465207C (en) Pyrazole-amides and -sulfonamides
ES2612686T3 (es) Derivados de quinoxalina
AU2008272964A1 (en) NMDA receptor antagonists for neuroprotection
US20090163482A1 (en) Tetralines antagonists of the h-3 receptor
CA2539479C (en) Isoquinoline potassium channel inhibitors
CA2507027A1 (en) Isoquinoline compounds and medicinal use thereof
US5246935A (en) Piperazinyl derivatives and methods of treating central nervous system ailments relating to the 5-ht2 receptor system
CA2908542A1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same
JP2006500348A5 (no)
RU2010119648A (ru) Пиразолы как 11-бета-hsd-1
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
WO2005105779A1 (en) 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006048209A1 (de) Neue bradykinin-b1-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
JPS61282367A (ja) 2−チオもしくはオキソ−4−アリ−ルまたはヘテロシクロ−1,5(2h)−ピリミジンジカルボン酸ジエステル類並びに3−アシル−5−ピリミジンカルボン酸類およびエステル類
MX2010012186A (es) Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos.
RS54629B1 (en) PYROLIDINONS AS METAP-2-INHIBITORS
NZ603724A (en) Piperidine derivatives and their use for the treatment of metabolic disorders
JP2007535478A5 (no)
AR124973A1 (es) Nuevos derivados de pirimidina-2-il sulfonamida